Jefferies says Jazz Pharmaceuticals' (JAZZ +16.6%) acquisition of EUSA will add $0.76 to its...

|About: Jazz Pharmaceuticals, Inc. (JAZZ)|By:, SA News Editor

Jefferies says Jazz Pharmaceuticals' (JAZZ +16.6%) acquisition of EUSA will add $0.76 to its FY13 earnings estimate and diversifies the company away from Xyrem. The firm now calls Jazz one of its top picks and raises its price target to $74.